RxDoctor Payments Data

Maritza Harrison

Family · Riverside, CANPI 1114237104

Payments from drug & device makers

$2,564in general payments, 2019–2025

Across 87 payments — averaging $29.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$653
  • Johnson & Johnson$409
  • Bayer$368
  • AstraZeneca$279
  • Novo Nordisk$269
  • GSK$123
  • plus $464 from 12 others

What the payments were for

  • Food & beverage$2,564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,564 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate76$50,358
FarxigaDapagliflozin Propanediol59$40,550
OzempicSemaglutide43$39,962
XareltoRivaroxaban66$39,022
JardianceEmpagliflozin63$36,446
KerendiaFinerenone19$16,908
DapagliflozinDapagliflozin Propanediol27$13,033
Tresiba Flextouch U-100Insulin Degludec25$10,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,875
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$7,479
SteglatroErtugliflozin Pidolate15$5,130
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$4,093
Trueplus Pen NeedlePen Needle, Diabetic63$3,116
Varenicline Tartrate13$2,312
Atorvastatin Calcium295$1,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$279$40,55059 claims
Novo NordiskOzempic$269$39,96243 claims
Johnson & JohnsonXarelto$409$39,02266 claims
Boehringer IngelheimJardiance$35$36,44663 claims
BayerKerendia$368$16,90819 claims
GSKTrelegy Ellipta$123$7,87511 claims
Lilly USA, LLCHumalog$74$65211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →